Smith Salley Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.2M | Buy |
59,398
+671
| +1% | +$364K | 1.47% | 18 |
|
|
2025
Q4 | $34M | Sell |
58,727
-119
| -0.2% | -$67.3K | 1.69% | 13 |
|
|
2025
Q3 | $28.5M | Buy |
58,846
+1,771
| +3% | +$824K | 1.47% | 18 |
|
|
2025
Q2 | $23.1M | Buy |
57,075
+1,415
| +3% | +$592K | 1.34% | 23 |
|
|
2025
Q1 | $27.7M | Buy |
55,660
+6,989
| +14% | +$3.79M | 1.82% | 14 |
|
|
2024
Q4 | $25.3M | Buy |
48,671
+5,954
| +14% | +$3.27M | 1.63% | 15 |
|
|
2024
Q3 | $26.4M | Buy |
42,717
+1,134
| +3% | +$671K | 1.73% | 13 |
|
|
2024
Q2 | $23M | Buy |
41,583
+2,240
| +6% | +$1.28M | 1.65% | 15 |
|
|
2024
Q1 | $22.9M | Sell |
39,343
-11,494
| -23% | -$6.45M | 1.77% | 14 |
|
|
2023
Q4 | $27M | Buy |
50,837
+1,774
| +4% | +$859K | 1.74% | 13 |
|
|
2023
Q3 | $24.8M | Buy |
49,063
+1,285
| +3% | +$685K | 1.84% | 15 |
|
|
2023
Q2 | $24.9M | Buy |
47,778
+658
| +1% | +$355K | 1.84% | 14 |
|
|
2023
Q1 | $27.2M | Buy |
47,120
+1,186
| +3% | +$668K | 2.16% | 7 |
|
|
2022
Q4 | $25.3M | Buy |
45,934
+216
| +0.5% | +$114K | 2.16% | 7 |
|
|
2022
Q3 | $23.2M | Buy |
45,718
+366
| +0.8% | +$205K | 2.16% | 7 |
|
|
2022
Q2 | $24.6M | Buy |
45,352
+1,724
| +4% | +$949K | 2.13% | 7 |
|
|
2022
Q1 | $25.8M | Buy |
43,628
+556
| +1% | +$319K | 1.95% | 8 |
|
|
2021
Q4 | $28.7M | Buy |
43,072
+356
| +0.8% | +$222K | 2.04% | 11 |
|
|
2021
Q3 | $24.4M | Buy |
42,716
+581
| +1% | +$319K | 1.92% | 13 |
|
|
2021
Q2 | $21.3M | Buy |
42,135
+1,158
| +3% | +$546K | 1.72% | 15 |
|
|
2021
Q1 | $18.7M | Buy |
40,977
+918
| +2% | +$438K | 1.68% | 18 |
|
|
2020
Q4 | $18.7M | Buy |
40,059
+1,514
| +4% | +$710K | 1.89% | 13 |
|
|
2020
Q3 | $17M | Buy |
38,545
+252
| +0.7% | +$104K | 2.06% | 11 |
|
|
2020
Q2 | $13.9M | Buy |
38,293
+1,636
| +4% | +$548K | 1.85% | 14 |
|
|
2020
Q1 | $10.4M | Buy |
36,657
+1,021
| +3% | +$322K | 1.73% | 16 |
|
|
2019
Q4 | $11.6M | Sell |
35,636
-559
| -2% | -$169K | 1.53% | 19 |
|
|
2019
Q3 | $10.5M | Buy |
36,195
+1,094
| +3% | +$313K | 1.5% | 20 |
|
|
2019
Q2 | $10.3M | Buy |
35,101
+1,385
| +4% | +$381K | 1.55% | 21 |
|
|
2019
Q1 | $9.23M | Buy |
33,716
+1,309
| +4% | +$326K | 1.49% | 22 |
|
|
2018
Q4 | $7.25M | Buy |
32,407
+963
| +3% | +$226K | 1.33% | 24 |
|
|
2018
Q3 | $7.67M | Buy |
31,444
+1,016
| +3% | +$234K | 1.21% | 29 |
|
|
2018
Q2 | $6.3M | Buy |
30,428
+856
| +3% | +$182K | 1.08% | 35 |
|
|
2018
Q1 | $6.11M | Buy |
29,572
+345
| +1% | +$72.4K | 1.09% | 35 |
|
|
2017
Q4 | $5.55M | Buy |
29,227
+737
| +3% | +$141K | 0.99% | 35 |
|
|
2017
Q3 | $5.39M | Buy |
28,490
+1,041
| +4% | +$189K | 1.03% | 38 |
|
|
2017
Q2 | $4.79M | Buy |
27,449
+25,270
| +1,160% | +$4.24M | 0.96% | 38 |
|
|
2017
Q1 | $335K | Buy |
2,179
+305
| +16% | +$46.6K | 0.07% | 129 |
|
|
2016
Q4 | $264K | Hold |
1,874
| – | – | 0.06% | 132 |
|
|
2016
Q3 | $298K | Sell |
1,874
-168
| -8% | -$25.9K | 0.07% | 125 |
|
|
2016
Q2 | $302K | Buy |
2,042
+63
| +3% | +$9.3K | 0.07% | 126 |
|
|
2016
Q1 | $280K | Hold |
1,979
| – | – | 0.07% | 127 |
|
|
2015
Q4 | $281K | Buy |
1,979
+73
| +4% | +$9.74K | 0.07% | 129 |
|
|
2015
Q3 | $233K | Buy |
1,906
+87
| +5% | +$11.3K | 0.06% | 136 |
|
|
2015
Q2 | $236K | Hold |
1,819
| – | – | 0.06% | 143 |
|
|
2015
Q1 | $244K | Buy |
1,819
+19
| +1% | +$2.45K | 0.06% | 147 |
|
|
2014
Q4 | $226K | Sell |
1,800
-14
| -0.8% | -$1.7K | 0.06% | 156 |
|
|
2014
Q3 | $221K | Buy |
1,814
+40
| +2% | +$4.86K | 0.06% | 163 |
|
|
2014
Q2 | $209K | Sell |
1,774
-26
| -1% | -$3.06K | 0.06% | 177 |
|
|
2014
Q1 | $216K | Buy |
+1,800
| New | +$214K | 0.14% | 104 |
|
Other funds holding TMO
VCM
Smith Salley Wealth Management's TMO Position: Q1 2026 in Review
Smith Salley Wealth Management increased its Thermo Fisher Scientific (TMO) stake by 1.1% in Q1 2026, buying an estimated $364K and bringing the position to 59,398 shares worth $29.2M. The position accounts for 1.47% of the portfolio, ranked #18.
Smith Salley Wealth Management first reported a position in TMO in Q1 2014 and has held it in 49 quarters since. The position peaked at $34M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Smith Salley Wealth Management held 59,398 shares of Thermo Fisher Scientific worth $29.2M as of Q1 2026.
- Smith Salley Wealth Management bought 671 Thermo Fisher Scientific shares in Q1 2026, an estimated $364K.
- Thermo Fisher Scientific made up 1.47% of Smith Salley Wealth Management's portfolio in Q1 2026, its #18 holding.
- Smith Salley Wealth Management first reported a position in Thermo Fisher Scientific in Q1 2014 and has held it in 49 quarters since.
- Smith Salley Wealth Management's Thermo Fisher Scientific position peaked at $34M in Q4 2025.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Smith Salley Wealth Management's 13F filing for Q1 2026, filed 16 Apr 2026.